Free Trial
NASDAQ:RNXT

RenovoRx (RNXT) Stock Price, News & Analysis

RenovoRx logo
$0.99 +0.03 (+3.14%)
Closing price 04:00 PM Eastern
Extended Trading
$0.98 -0.01 (-0.72%)
As of 04:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About RenovoRx Stock (NASDAQ:RNXT)

Key Stats

Today's Range
$0.97
$1.01
50-Day Range
$0.77
$1.07
52-Week Range
$0.75
$1.69
Volume
112,646 shs
Average Volume
75,691 shs
Market Capitalization
$36.19 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.00
Consensus Rating
Buy

Company Overview

RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.

RenovoRx Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
43rd Percentile Overall Score

RNXT MarketRank™: 

RenovoRx scored higher than 43% of companies evaluated by MarketBeat, and ranked 489th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    RenovoRx has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    RenovoRx has only been the subject of 2 research reports in the past 90 days.

  • Read more about RenovoRx's stock forecast and price target.
  • Earnings Growth

    Earnings for RenovoRx are expected to decrease in the coming year, from ($0.40) to ($0.46) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of RenovoRx is -1.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of RenovoRx is -1.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about RenovoRx's valuation and earnings.
  • Percentage of Shares Shorted

    0.84% of the float of RenovoRx has been sold short.
  • Short Interest Ratio / Days to Cover

    RenovoRx has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in RenovoRx has recently increased by 12.12%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    RenovoRx does not currently pay a dividend.

  • Dividend Growth

    RenovoRx does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.84% of the float of RenovoRx has been sold short.
  • Short Interest Ratio / Days to Cover

    RenovoRx has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in RenovoRx has recently increased by 12.12%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    RenovoRx has a news sentiment score of 0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.84 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for RenovoRx this week, compared to 1 article on an average week.
  • Search Interest

    2 people have searched for RNXT on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, RenovoRx insiders have bought more of their company's stock than they have sold. Specifically, they have bought $90,218.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    Only 7.10% of the stock of RenovoRx is held by insiders.

  • Percentage Held by Institutions

    Only 3.10% of the stock of RenovoRx is held by institutions.

  • Read more about RenovoRx's insider trading history.
Receive RNXT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for RenovoRx and its competitors with MarketBeat's FREE daily newsletter.

RNXT Stock News Headlines

Massive new energy source found in Utah
NEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millions of years. And both grizzled oilmen and clean energy supporters love it: Energy Secretary Chris Wright called it "an awesome resource," while Warren Buffett, Jeff Bezos, Mark Zuckerberg, and Bill Gates are all directly invested.
See More Headlines

RNXT Stock Analysis - Frequently Asked Questions

RenovoRx's stock was trading at $1.29 on January 1st, 2025. Since then, RNXT shares have decreased by 23.2% and is now trading at $0.9901.
View the best growth stocks for 2025 here
.

RenovoRx, Inc. (NASDAQ:RNXT) posted its earnings results on Monday, March, 31st. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.12) by $0.01. The firm earned $0.04 million during the quarter, compared to the consensus estimate of $0.17 million.

RenovoRx (RNXT) raised $18 million in an IPO on Thursday, August 26th 2021. The company issued 1,800,000 shares at a price of $9.00-$11.00 per share. Roth Capital Partners and Maxim Group LLC served as the underwriters for the IPO.

Shares of RNXT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that RenovoRx investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Nano Dimension (NNDM), AST SpaceMobile (ASTS), Bakkt (BKKT), NIO (NIO) and Phunware (PHUN).

Company Calendar

Last Earnings
3/31/2025
Today
5/01/2025
Next Earnings (Estimated)
5/09/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:RNXT
Employees
6
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$7.00
High Stock Price Target
$11.00
Low Stock Price Target
$3.00
Potential Upside/Downside
+607.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-10,230,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$43,000.00
Price / Cash Flow
N/A
Book Value
($0.28) per share
Price / Book
-3.54

Miscellaneous

Free Float
22,297,000
Market Cap
$36.19 million
Optionable
Not Optionable
Beta
1.12
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

This page (NASDAQ:RNXT) was last updated on 5/1/2025 by MarketBeat.com Staff
From Our Partners